The efficacy of pindolol in reducing weight gain associated with the use of Olanzapine
Completed
- Conditions
- ObesityNutritional, Metabolic, Endocrine
- Registration Number
- ISRCTN87255415
- Lead Sponsor
- Record provided by the NHS Trusts Clinical Trials Register - Department of Health (UK)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 36
Inclusion Criteria
36 Participants, who will be recruited through the clinicians working with Camden and Islington Mental Health and Social Care Trust.
Exclusion Criteria
Not provided at time of registration
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Olanzapine is commonly used in the treatment of schizophrenia. Whilst generally well tolerated, weight gain is known to effect compliance and acceptability to many patients. In patients who continue to take Olanzapine despite gaining weight there are general health and psychological ramifications. If weight gain could be minimised then this burden may be reduced, leading to a lessening of pressure upon NHS resources.
- Secondary Outcome Measures
Name Time Method ot provided at time of registration